why choose us

300×250 Ad Slot

Research Article: A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Date Published: 2023-07-13

Introduction:
Diffuse large B-cell lymphoma (DLBCL) is a group of B cell-derived malignant tumors with obvious heterogeneity. After obtaining standardized treatment, a sizeable portion of DLBCL patients can be cured and survive for a long time. However, roughly one-third of DLBCL patients experience drug resistance and disease recurrence. , Therefore, it is essential to identify high-risk patients as early as possible and develop and modify treatment plans as needed to maximize the survival benefits of patients.

Read more

300×250 Ad Slot